metformin has been researched along with Arterial Diseases, Carotid in 9 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Metformin is a widely used classic antidiabetic drug." | 2.80 | Metformin ameliorates the proinflammatory state in patients with carotid artery atherosclerosis through sirtuin 1 induction. ( Deng, YY; Gao, S; Liu, J; Maharjan, P; Tian, Y; Wang, L; Wu, Y; Xu, W; Yang, L; Yuan, Z; Zhao, S; Zhao, Y; Zhao, Z; Zhou, J; Zhuo, X, 2015) |
| "Metformin is a well-known oral hypoglycaemic agent and has been commonly used, in combination with sulphonylurea, to treat type 2 diabetes." | 2.71 | Metformin or gliclazide, rather than glibenclamide, attenuate progression of carotid intima-media thickness in subjects with type 2 diabetes. ( Hayaishi-Okano, R; Hori, M; Kaneto, H; Katakami, N; Kosugi, K; Matsuhisa, M; Ohtoshi, K; Yamasaki, Y, 2004) |
| "Metformin treatment was associated with decreased NGAL [60." | 1.46 | Neutrophil gelatinase associated lipocalin (NGAL) is elevated in type 2 diabetics with carotid artery stenosis and reduced under metformin treatment. ( Demyanets, S; Eilenberg, W; Huk, I; Kaider, A; Kozakowski, N; Nanobachvili, J; Neumayer, C; Piechota-Polanczyk, A; Stojkovic, S; Weninger, WJ; Wojta, J, 2017) |
| "Inflammation has been proposed as the main cause for the high risk of atherosclerotic disease in DM II." | 1.40 | Impaired fibrous repair: a possible contributor to atherosclerotic plaque vulnerability in patients with type II diabetes. ( Bengtsson, E; Björkbacka, H; Dunér, P; Edsfeldt, A; Gonçalves, I; Grufman, H; Melander, O; Mollet, IG; Nilsson, J; Nilsson, M; Nitulescu, M; Orho-Melander, M; Persson, A, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (22.22) | 29.6817 |
| 2010's | 5 (55.56) | 24.3611 |
| 2020's | 2 (22.22) | 2.80 |
| Authors | Studies |
|---|---|
| Sposito, AC | 2 |
| Breder, I | 2 |
| Soares, AAS | 2 |
| Kimura-Medorima, ST | 2 |
| Munhoz, DB | 2 |
| Cintra, RMR | 1 |
| Bonilha, I | 1 |
| Oliveira, DC | 1 |
| Breder, JC | 1 |
| Cavalcante, P | 1 |
| Moreira, C | 1 |
| Moura, FA | 1 |
| de Lima-Junior, JC | 1 |
| do Carmo, HRP | 1 |
| Barreto, J | 2 |
| Nadruz, W | 2 |
| Carvalho, LSF | 1 |
| Quinaglia, T | 2 |
| Wolf, VLW | 1 |
| de Carvalho, LSF | 1 |
| Cintra, RM | 1 |
| Guerra-Júnior, G | 1 |
| Muscelli, E | 1 |
| Eilenberg, W | 1 |
| Stojkovic, S | 1 |
| Piechota-Polanczyk, A | 1 |
| Kaider, A | 1 |
| Kozakowski, N | 1 |
| Weninger, WJ | 1 |
| Nanobachvili, J | 1 |
| Wojta, J | 1 |
| Huk, I | 1 |
| Demyanets, S | 1 |
| Neumayer, C | 1 |
| Edsfeldt, A | 1 |
| Gonçalves, I | 1 |
| Grufman, H | 1 |
| Nitulescu, M | 1 |
| Dunér, P | 1 |
| Bengtsson, E | 1 |
| Mollet, IG | 1 |
| Persson, A | 1 |
| Nilsson, M | 1 |
| Orho-Melander, M | 1 |
| Melander, O | 1 |
| Björkbacka, H | 1 |
| Nilsson, J | 1 |
| Xu, W | 1 |
| Deng, YY | 1 |
| Yang, L | 1 |
| Zhao, S | 1 |
| Liu, J | 1 |
| Zhao, Z | 1 |
| Wang, L | 1 |
| Maharjan, P | 1 |
| Gao, S | 1 |
| Tian, Y | 1 |
| Zhuo, X | 1 |
| Zhao, Y | 1 |
| Zhou, J | 1 |
| Yuan, Z | 1 |
| Wu, Y | 1 |
| Rizzo, M | 1 |
| Rizvi, AA | 1 |
| Patti, AM | 1 |
| Nikolic, D | 1 |
| Giglio, RV | 1 |
| Castellino, G | 1 |
| Li Volti, G | 1 |
| Caprio, M | 1 |
| Montalto, G | 1 |
| Provenzano, V | 1 |
| Genovese, S | 1 |
| Ceriello, A | 1 |
| Joya-Galeana, J | 1 |
| Fernandez, M | 1 |
| Cervera, A | 1 |
| Reyna, S | 1 |
| Ghosh, S | 1 |
| Triplitt, C | 1 |
| Musi, N | 1 |
| DeFronzo, RA | 1 |
| Cersosimo, E | 1 |
| Matsumoto, K | 1 |
| Sera, Y | 1 |
| Abe, Y | 1 |
| Tominaga, T | 1 |
| Yeki, Y | 1 |
| Miyake, S | 1 |
| Katakami, N | 1 |
| Yamasaki, Y | 1 |
| Hayaishi-Okano, R | 1 |
| Ohtoshi, K | 1 |
| Kaneto, H | 1 |
| Matsuhisa, M | 1 |
| Kosugi, K | 1 |
| Hori, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Dapagliflozin on Cardio-Metabolic Risk Factors in Patients With Type-2 Diabetes[NCT03377335] | Phase 4 | 186 participants (Anticipated) | Interventional | 2017-12-22 | Active, not recruiting | ||
| Effects of Liraglutide on Cardio-Metabolic Risk Markers[NCT01715428] | 300 participants (Actual) | Observational | 2012-06-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
6 trials available for metformin and Arterial Diseases, Carotid
| Article | Year |
|---|---|
Dapagliflozin effect on endothelial dysfunction in diabetic patients with atherosclerotic disease: a randomized active-controlled trial.
Topics: Adult; Aged; Benzhydryl Compounds; Biomarkers; Blood Glucose; Brazil; Carotid Artery Diseases; Diabe | 2021 |
Dapagliflozin increases the lean-to total mass ratio in type 2 diabetes mellitus.
Topics: Absorptiometry, Photon; Adult; Aged; Benzhydryl Compounds; Blood Glucose; Body Composition; Body Wei | 2021 |
Metformin ameliorates the proinflammatory state in patients with carotid artery atherosclerosis through sirtuin 1 induction.
Topics: Aged; Arteriosclerosis; Carotid Artery Diseases; Female; Humans; Inflammation; Male; Metformin; Midd | 2015 |
Liraglutide improves metabolic parameters and carotid intima-media thickness in diabetic patients with the metabolic syndrome: an 18-month prospective study.
Topics: Aged; Biomarkers; Carotid Artery Diseases; Carotid Intima-Media Thickness; Diabetes Mellitus, Type 2 | 2016 |
Liraglutide improves metabolic parameters and carotid intima-media thickness in diabetic patients with the metabolic syndrome: an 18-month prospective study.
Topics: Aged; Biomarkers; Carotid Artery Diseases; Carotid Intima-Media Thickness; Diabetes Mellitus, Type 2 | 2016 |
Liraglutide improves metabolic parameters and carotid intima-media thickness in diabetic patients with the metabolic syndrome: an 18-month prospective study.
Topics: Aged; Biomarkers; Carotid Artery Diseases; Carotid Intima-Media Thickness; Diabetes Mellitus, Type 2 | 2016 |
Liraglutide improves metabolic parameters and carotid intima-media thickness in diabetic patients with the metabolic syndrome: an 18-month prospective study.
Topics: Aged; Biomarkers; Carotid Artery Diseases; Carotid Intima-Media Thickness; Diabetes Mellitus, Type 2 | 2016 |
Effects of insulin and oral anti-diabetic agents on glucose metabolism, vascular dysfunction and skeletal muscle inflammation in type 2 diabetic subjects.
Topics: Adult; Body Mass Index; Carotid Arteries; Carotid Artery Diseases; Diabetes Mellitus, Type 2; Diabet | 2011 |
Metformin or gliclazide, rather than glibenclamide, attenuate progression of carotid intima-media thickness in subjects with type 2 diabetes.
Topics: Carotid Arteries; Carotid Artery Diseases; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fem | 2004 |
3 other studies available for metformin and Arterial Diseases, Carotid
| Article | Year |
|---|---|
Neutrophil gelatinase associated lipocalin (NGAL) is elevated in type 2 diabetics with carotid artery stenosis and reduced under metformin treatment.
Topics: Aged; Biomarkers; Carotid Arteries; Carotid Artery Diseases; Carotid Stenosis; Diabetes Mellitus, Ty | 2017 |
Impaired fibrous repair: a possible contributor to atherosclerotic plaque vulnerability in patients with type II diabetes.
Topics: Aged; Antihypertensive Agents; Carotid Artery Diseases; Cytokines; Diabetes Mellitus, Type 2; Diseas | 2014 |
Metformin attenuates progression of carotid arterial wall thickness in patients with type 2 diabetes.
Topics: Arteriosclerosis; Carotid Arteries; Carotid Artery Diseases; Chronic Disease; Diabetes Mellitus, Typ | 2004 |